Changzhou Qianhong Bio Pharma Co., Ltd formulation plant

Changzhou, ChinaFEI 3005275502

Changzhou Qianhong Bio Pharma Co., Ltd formulation plant is a drug establishment in Changzhou, China, registered with the US FDA under FEI 3005275502. Its registered operations are: Analytical testing. 3 EU/UK GMP certificates are matched to this site, 1 inspected within the last three years; 2 have since been withdrawn by the issuing authority. FDA has published 6 inspection outcomes for this FEI; the most recent, ended 31 Oct 2025, was classified voluntary action indicated (VAI).

Sources: FDA Drug Establishments Current Registration Site (checked 16 Nov 2026); FDA Data Dashboard (inspections); EudraGMDP; MHRA GMDP. Methodology

Cite as: PharmaTek, “Changzhou Qianhong Bio Pharma Co., Ltd formulation plant: FDA registration, inspection and GMP record (FEI 3005275502)”, record as of 16 Nov 2026, pharmatek.co.uk/manufacturing-sites/changzhou-qianhong-bio-pharma-co-ltd-formulation-plant-changzhou-3005275502

Registered operations

Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.

Analytical testing

GMP documents matched to this site (3)

DocumentAuthorityInspectionSource
DE_HH_01_GMP_2026_0012
GMP certificate
Competent authority of Germany16 Apr 2026
within 3-year review window
EudraGMDP
DE_HH_01_GMP_2023_0041
GMP certificate
Competent authority of Germany10 May 2023
Superseded by a newer certificate; withdrawn on 2 Oct 2023
Register note: GMP certificate has been superseded by document with the number DE_HH_01_GMP_2023_0042
EudraGMDP
DE_HH_01_GMP_2023_0042
GMP certificate
Competent authority of Germany10 May 2023
Superseded by a newer certificate; withdrawn on 22 May 2026
Register note: GMP certificate has been superseded by document with the number DE_HH_01_GMP_2026_0012
EudraGMDP

A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.

FDA inspection outcomes (6)

Inspection endedOutcomeProgramme areaCitations posted
31 Oct 2025VAI · Voluntary action indicatedDrug Quality AssuranceNo
10 May 2023VAI · Voluntary action indicatedDrug Quality AssuranceNo
23 Oct 2019NAI · No action indicatedDrug Quality AssuranceNo
15 Dec 2017VAI · Voluntary action indicatedDrug Quality AssuranceNo
1 Aug 2014VAI · Voluntary action indicatedDrug Quality AssuranceNo
30 Apr 2010NAI · No action indicatedDrug Quality AssuranceNo

FDA Data Dashboard, joined on the FEI. NAI: no objectionable conditions found. VAI: objectionable conditions found, but not serious enough for regulatory action. OAI: regulatory or administrative action recommended. A classification describes one inspection on one date; FDA publishes it only once final and does not publish every inspection. FDA firm profile

FDA warning letters (1)

FDA Data Dashboard, drug products, issued against FEI 3005275502. A warning letter may since have been closed out; FDA publishes close-out letters separately.

What this page does not show

  • Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
  • Capacity, scale, price or current availability: no regulator publishes these.
  • The full text of a Form 483 or warning letter: FDA's dashboard gives the regulation cited and a short description only.
For suppliers

Is this CHANGZHOU QIANHONG BIO PHARMA CO LTD?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.